Drug intelligence / Profile preview

Suhe Granules

Development stage: Phase 2
Lead developer: Chongqing Juqinuomei Pharmaceutical
Administration: Oral

Overview

Suhe Granules (苏合颗粒) is a 1.1-class innovative Traditional Chinese Medicine (TCM) drug developed through a collaboration between Chongqing Juqi Nuomei Pharmaceutical and Beijing University of Chinese Medicine. It is an oral herbal formulation based on classical experience formulas, specifically developed under the leadership of Professor Wang Ting. As a multi-component TCM preparation, it does not have a single defined molecular target but operates through the synergistic effects of its herbal constituents. The drug received clinical trial approval from China's National Medical Products Administration (NMPA) in early 2023 (Approval No. 2023LP00288) and is currently in Phase 1 clinical development. Its research and development were supported by the National Science and Technology Major Project.

Other names: 苏合颗粒Suhe Granules

Beyond the preview

Go deeper on Suhe Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suhe Granules.